Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Home > News > Publications > Documents > Research Reports > Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Download Download 797

Views 1149

Details

No details.

Health Intervention and Technology Assessment Program Foundation
Head Office : 88/22 Moo 4, 6th Building, 6th Floor, Department of Health, Ministry of Public Health, Tiwanon Road, Taladkwan Subdistrict, Muang Nonthaburi District, Nonthaburi 11000, Thailand

Tel. : +662-590-4549, +662-590-4374-5
Fax : +662-590-4369
E-mail : [email protected]
Website : www.hitap.net

Follow Us On

Subscribe to our mailing list

Email address*

Name*

This field should be left blank

Subscribe to our mailing list

* indicates required

Email Address *

First Name

Last Name

Top

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Cookie Policy

More information about our Cookie Policy

HITAP เข้าสู่ระบบ

Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Details

Menu

Follow Us On

Subscribe to our mailing list

Subscribe to our mailing list